Lite Strategy, Inc.

LITS · Nasdaq · SIC 2834: Pharmaceutical Preparations
356
SEC Filings

Business Summary

Lite Strategy, Inc. (formerly MEI Pharma, Inc.) is a pharmaceutical company developing novel cancer therapies, with drug candidates voruciclib (oral CDK9 inhibitor) and zandelisib (oral PI3K inhibitor). In August 2025, following a $100 million PIPE, the company implemented a Litecoin Treasury Strategy by acquiring Litecoin (LTC) tokens as its primary reserve asset, while continuing to assess pre-clinical drug development activities.

Next Earnings

Q2 FY2026 — expected 2026-09-12

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionLITSdiscussed_in_filing Blockchain & Crypto
topic_mentionLITSdiscussed_in_filing Healthcare & Bio
topic_mentionLITSdiscussed_in_filing Blockchain & Crypto
topic_mentionLITSdiscussed_in_filing Healthcare & Bio
topic_mentionLITSdiscussed_in_filing Blockchain & Crypto
topic_mentionLITSdiscussed_in_filing Healthcare & Bio
topic_mentionLITSdiscussed_in_filing Blockchain & Crypto
topic_mentionLITSdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-09-262025-06-300001193125-25-220421EDGAR65K words
2024-09-192024-06-300000950170-24-108185EDGAR—
2023-09-262023-06-300000950170-23-049927EDGAR—
2022-09-082022-06-300000950170-22-018236EDGAR—
2021-09-022021-06-300000950170-21-001655EDGAR—
2020-09-092020-06-300001193125-20-242169EDGAR—
2019-08-282019-06-300001193125-19-232454EDGAR—
2018-08-302018-06-300001193125-18-263586EDGAR—
2017-09-052017-06-300001193125-17-276135EDGAR—
2016-09-062016-06-300001193125-16-701415EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-172025-12-310001193125-26-053215EDGAR27K words
2025-11-142025-09-300001193125-25-283111EDGAR—
2025-05-132025-03-310000950170-25-070276EDGAR—
2025-02-122024-12-310000950170-25-018809EDGAR—
2024-11-122024-09-300000950170-24-125328EDGAR—
2024-05-092024-03-310000950170-24-056834EDGAR—
2024-02-132023-12-310000950170-24-014640EDGAR—
2023-11-092023-09-300000950170-23-061976EDGAR—
2023-05-112023-03-310000950170-23-021179EDGAR—
2023-02-092022-12-310000950170-23-002323EDGAR—
2022-11-142022-09-300000950170-22-024967EDGAR—
2022-05-232022-03-310000950170-22-010498EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-170001193125-26-053243EDGAR1K words
2026-02-120001193125-26-049005EDGAR—
2025-12-300001193125-25-335761EDGAR—
2025-12-050001193125-25-309593EDGAR—
2025-11-180001193125-25-286424EDGAR—
2025-10-300001193125-25-258474EDGAR—
2025-09-150001193125-25-203520EDGAR—
2025-09-100001262104-25-000009EDGAR—
2025-09-040000929638-25-003398EDGAR—
2025-08-060000950170-25-103990EDGAR—

356 total filings indexed. 324 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

oncology-/-cancer-therapeutics digital-assets-/-cryptocurrency cdk9-inhibition pi3k-delta-inhibition litecoin-(ltc)-blockchain

Company Identity

CIK0001262104
TickerLITS
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 5ceaa9c9ce5e6369e6d11fcc198a9f7978527cdbc8a4db29dad6653473de4f34
parent: 6f87826b8fa9118a9806eb79ddeb320f82ee6083daf1570b4795a35b3cdfdafd
content hash: 578ba54de6fe6a219ce23844478ed2760c120257340d39d52c084ceef5fe9d2e
signed: 2026-04-13T04:46:03.106Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf